Your session is about to expire
← Back to Search
AZD7442 for Coronavirus (STORM CHASER Trial)
Phase 3
Waitlist Available
Led By Myron Levin, MD
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up planned to be evaluated through day 183, however, the number of participants required was achieved 127 days after the study start date
Awards & highlights
Pivotal Trial
Summary
This study will assess the efficacy of AZD7442 for the post-exposure prophylaxis of COVID-19 in Adults.
Eligible Conditions
- Coronavirus
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ planned to be evaluated through day 183, however, the number of participants required was achieved 127 days after the study start date
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~planned to be evaluated through day 183, however, the number of participants required was achieved 127 days after the study start date
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of Participants With First Case of SARS-CoV-2 RT-PCR Positive Symptomatic Illness
Side effects data
From 2023 Phase 3 trial • 5197 Patients • NCT0462572513%
Headache
13%
Covid-19
12%
Cough
11%
Fatigue
9%
Rhinorrhoea
9%
Oropharyngeal pain
8%
Nasal congestion
5%
Dyspnoea
5%
Pain
5%
Myalgia
5%
Diarrhoea
5%
Nausea
4%
Urinary tract infection
4%
Chills
4%
Pyrexia
4%
Arthralgia
3%
Hypertension
2%
Vomiting
2%
Anosmia
2%
Decreased appetite
2%
Dizziness
2%
Upper respiratory tract infection
2%
Vaccination complication
2%
Back pain
2%
Ageusia
1%
Asthma
1%
Muscle spasms
1%
Insomnia
1%
Pulmonary congestion
1%
Hypercholesterolaemia
1%
Migraine
1%
Constipation
1%
Fall
1%
Anaemia
1%
Contusion
1%
Asthenia
1%
Sneezing
1%
Pneumonia
1%
Sinusitis
1%
Pruritus
1%
Anxiety
1%
Abdominal pain
1%
Chronic obstructive pulmonary disease
1%
Ligament sprain
1%
Hyperglycaemia
1%
Type 2 diabetes mellitus
1%
Osteoarthritis
1%
Pain in extremity
1%
Vitamin d deficiency
1%
Sinus congestion
1%
Rash
1%
Gastrooesophageal reflux disease
1%
Cystitis
1%
Gastroenteritis
1%
Depression
1%
Haematuria
1%
Lower respiratory tract infection
1%
Productive cough
1%
Asymptomatic covid-19
1%
Rhinitis
1%
Viral infection
1%
Blood creatine phosphokinase increased
1%
Nasopharyngitis
1%
Influenza like illness
1%
Injection site pain
1%
Malaise
1%
Seasonal allergy
1%
Abdominal pain upper
1%
Bronchitis
1%
Skin laceration
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
AZD7442
Awards & Highlights
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: AZD7442Experimental Treatment1 Intervention
Participants will be randomized in a 2:1 ratio to receive a single dose (× 2 IM injections) of either 300 mg of AZD7442 (n = approximately 750) or saline placebo (n = approximately 375) on Day 1.
Group II: PlaceboPlacebo Group1 Intervention
Participants will be randomized in a 2:1 ratio to receive a single dose (× 2 IM injections) of either 300 mg of AZD7442 (n = approximately 750) or saline placebo (n = approximately 375) on Day 1.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AZD7442
2021
Completed Phase 3
~13290
Find a Location
Who is running the clinical trial?
AstraZenecaLead Sponsor
4,400 Previous Clinical Trials
289,121,601 Total Patients Enrolled
Iqvia Pty LtdIndustry Sponsor
116 Previous Clinical Trials
173,439 Total Patients Enrolled
Myron Levin, MDPrincipal InvestigatorAstraZeneca
4 Previous Clinical Trials
5,359 Total Patients Enrolled
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger